Navigation Links
Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
Date:10/7/2009

elected to the National Academy of Sciences in 1990. In 2001, Dr. Steitz together with Drs. Moore and Noller received the Rosenstiel Award for Distinguished Work in Basic Medical Sciences for their research on the ribosome. Currently, Dr. Steitz is the Sterling Professor of Molecular Biophysics and Biochemistry and a Howard Hughes Medical Institute Investigator at Yale University. His research in the field of protein and nucleic acid X-ray crystallography, including his recent work with Dr. Moore on the 50S ribosome structure has had wide-ranging impact in the global scientific community.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics, including radezolid, that can be used for the treatment of either community- or hospital-acquired infections. Delafloxacin (RX-3341) is a Phase 3-ready broad-spectrum fluoroquinolone with potent activity against quinolone-resistant Gram-positive bacteria, including methicillin-resistant S. aureus. Radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X as an oral/IV agent for treatment of serious Gram-positive infections, has completed two Phase 2 trials. The Rx-04 discovery progra
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
6. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
7. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)...  Cardica, Inc. (Nasdaq: CRDC ) today announced ... quarter and year ended June 30, 2014, on Thursday, August ... a conference call at 4:30 p.m. Eastern Time to discuss ... business. Conference Call Details To access the live ... Time via phone, please dial 866-953-6859 from the ...
(Date:7/23/2014)... -- Global healthcare company GSK reports Q2 ... increased price competition and supply disruptions to its Consumer ... points out that the company is very much in transition, ... confident about long-term prospects as well as the investments ... Simon Dingemans adds that the company is ...
(Date:7/23/2014)... ENGLEWOOD, Colo. , July 23 2014 ... opening of its new headquarters, manufacturing and research facility: ... Englewood, CO 80112 Direct: (720) 437-6500 ... advanced, labor efficient, pharmaceutical drug manufacturing facility will be ... to produce the first batches of Ampion TM ...
Breaking Medicine Technology:Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2
... Pa., Feb. 16, 2011 AirPal, a medical device ... of allowance from the U.S. Patent Office for its ... for situations such as difficult airway management, laryngoscopies, diagnostic ... founded in 1982, now holds more than a dozen ...
... YORK, Feb. 16, 2011 Get content from ... The European Parliament is expected ... prevent falsified medicines from entering the legal distribution ... packages have reached patients in the last years. ...
Cached Medicine Technology:AirPal Receives Patent for Inflatable Patient Positioning Systems 2
(Date:7/23/2014)... of research suggesting a safe and effective role ... cancer, with fewer detrimental side effects and improved ... study will be published in final format today ... Endocrinology . , Breast cancer is the most ... States. Approximately 70% of breast cancers are diagnosed ...
(Date:7/23/2014)... of Biomedical Imaging and Bioengineering will host its second ... 2014 on the NIH campus. There will be ten ... breadth of NIBIB-funded research. , WHO: ... Rhodopsins as Optical Voltage Sensor, Quyen Nguyen, Univ. ... Nerve Imaging during Surgery, ...
(Date:7/23/2014)... 2014 The American Telemedicine Association ... twentieth annual meeting and tradeshow focused exclusively on ... attract over 5,000 attendees and more than 250 ... 3-5, 2015, in Los Angeles. , ATA’s annual ... professionals from researchers, clinicians, hospital and university administrators, ...
(Date:7/23/2014)... New York (PRWEB) July 23, 2014 ... continue to move forward in a federal multidistrict litigation ... Bernstein Liebhard LLP reports. According to an Order dated ... a hospital’s bid for payment of a $1,000 fee ... hip implant. , Among other things, the Order ...
(Date:7/23/2014)... Fragile X syndrome ( FXS ) is a ... other behaviors on the autistic spectrum, as well as ... of mental impairment and the most common cause of ... California, Riverside have published a study that ... FXS. Appearing online today (July 23) in the ...
Breaking Medicine News(10 mins):Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 4Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3
... 6, 2009) The American Association of Pharmaceutical Scientists ... Ph.D., to the position of Research Fellow at the ... she will begin work this week to develop effective ... appointment comes at the end of a collaborative effort ...
... 12th annual Boston Stroke Luncheon "Making the Stroke Connection" will ... Boston from 7:30 a.m. to 12 p.m. Activities include a ... End Stroke Ambassador Training, and an awards celebration lunch from ... Janet Wu. , Milton Resident Margaret Kelly-Hayes, EdD, ...
... big chunk of change" to make Jen Ross smile. This ... raise more than $1,000 for Custom Hearts , ... heart defects or heart disease."Now that we have a big chunk ... things that we,ve wanted to do for a year and a ...
... Misperceptions About Donation Are CommonRICHMOND, Va., April 14 ... organ and tissue donors is rising, the registry still ... a report card issued by Donate Life America this ... Americans, 72 percent of people want their decision to ...
... Nu Skin Enterprises, Inc. (NYSE: NUS ) ... to the market opening on April 30, 2009. Truman ... call with the investment community later that same day beginning ... expect to hear management discuss past results as well as ...
... Association Becomes Only Major Parkinson,s Organization to Launch ... Parkinson,s DiseaseSTATEN ISLAND, N.Y., April 14 The ... Center has launched a re-designed Web site, ... onset Parkinson,s disease (PD), their family members, friends, ...
Cached Medicine News:Health News:AAPS and FDA announce appointment of research fellow 2Health News:Milton resident receives the Helen B. Spaulding Community Conscience Award 2Health News:TAN's Efforts Produce 'Chunk of Change' for Children With Heart Defects 2Health News:While the Majority of Americans Express Interest in Organ and Tissue Donation, Too Few Take Steps to Register as Donors 2Health News:While the Majority of Americans Express Interest in Organ and Tissue Donation, Too Few Take Steps to Register as Donors 3Health News:New Young Onset Parkinson's Disease Web Site Goes Live 2Health News:New Young Onset Parkinson's Disease Web Site Goes Live 3
Mounted on a sturdy, molded headband,the Classic has a fully adjustable crown,strap and cushioning that adds to,your comfort....
The Convertible lets you attach the,High Lite optic directly to your loupes....
... is a product of AlloSource, one ... human tissue processing, and Interpore Cross, ... InterGro combines AlloGro DBM with ... deliver a unique bone graft that ...
Immunoassay for the detection of Group A streptococcal antigen directly from throat swab specimens. ,Rapid, accurate diagnosis assures prompt treatment....
Medicine Products: